+357 96 030922
info@marketpublishers.com

Global AR PROTAC Degraders Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GF8CA2D373A8EN.html
Date: January 2026
Pages: 98
Price: US$ 4,480.00 (Single User License)
ID: GF8CA2D373A8EN

Abstracts

The global AR PROTAC Degraders market size is expected to reach $ 494 million by 2032, rising at a market growth of 18.2% CAGR during the forecast period (2026-2032).

No AR PROTAC Degraders have yet been approved for market launch. Drugs from major manufacturers are currently in the pipeline research and clinical trial stages, in a critical sprint before market launch, and the competitive landscape is beginning to emerge.

AR PROTAC Degraders are targeted protein degraders designed to eliminate the androgen receptor (AR) protein inside cells rather than simply blocking it. They are typically heterobifunctional small molecules with three parts: (1) an AR-binding ligand that attaches to the androgen receptor, (2) an E3 ligase–recruiting ligand (commonly CRBN or VHL) that brings in the cell's ubiquitin machinery, and (3) a linker connecting the two. By forming a ternary complex (AR–PROTAC–E3 ligase), they promote ubiquitination of AR and subsequent proteasomal degradation, which can provide deeper pathway suppression and may help overcome some resistance mechanisms seen with conventional AR antagonists.

AR PROTAC Degraders are attracting outsized attention because they aim to solve a central pain point in androgen-driven disease—especially advanced prostate cancer—where simply blocking the androgen receptor can fail as tumors adapt through receptor overexpression, activating mutations, or pathway rewiring; by inducing selective degradation of the AR protein itself, PROTACs offer the potential for deeper and more durable pathway suppression and a way to restore control in settings where conventional antagonists lose traction. This "event-driven" mechanism can translate into meaningful advantages in practice: activity at lower effective target occupancy than

+357 96 030922
info@marketpublishers.com

inhibitors, the possibility of overcoming certain resistance patterns tied to sustained receptor signaling, and a clearer rationale for combination strategies that are limited today by overlapping toxicities or diminishing incremental benefit. The industry is being propelled by converging drivers—validated clinical proof-of-concept for targeted protein degradation, accelerating medicinal chemistry and structural biology that improve oral drug-like properties and selectivity, a strong need for differentiated assets in crowded hormonal therapy markets, and a financing and partnering environment that rewards platform technologies capable of generating multiple candidates across targets. Looking ahead, AR PROTACs are likely to evolve from a niche “last-line salvage” concept into a competitive therapeutic class where next-generation molecules differentiate on safety, tolerability, and performance against real-world resistance, with market potential expanding as clinical positioning becomes clearer, physician confidence grows, and manufacturing and regulatory pathways mature for this now-established but still rapidly innovating modality.

AR PROTAC Degraders' upstream raw materials mainly include AR Targeted Ligands, E3 ligase ligands, Linker, excipients, etc. Typical suppliers include Bio-Techne, Merck, Sigma-Aldrich, Enamine, etc., while downstream applications are mainly in the treatment of prostate cancer and other diseases.

This report studies the global AR PROTAC Degraders production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for AR PROTAC Degraders and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of AR PROTAC Degraders that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global AR PROTAC Degraders total production and demand, 2021-2032, (K Units)

Global AR PROTAC Degraders total production value, 2021-2032, (USD Million)

Global AR PROTAC Degraders production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)

Global AR PROTAC Degraders consumption by region & country, CAGR, 2021-2032 &

+357 96 030922
info@marketpublishers.com

(K Units)

U.S. VS China: AR PROTAC Degraders domestic production, consumption, key domestic manufacturers and share

Global AR PROTAC Degraders production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)

Global AR PROTAC Degraders production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

Global AR PROTAC Degraders production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

This report profiles key players in the global AR PROTAC Degraders market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BMS, Arvinas, Novartis, Genentech, Hinova Pharmaceuticals, Jiangsu Hengrui Medicine, Kintor Pharmaceutical, Qilu Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World AR PROTAC Degraders market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global AR PROTAC Degraders Market, By Region:

United States

+357 96 030922
info@marketpublishers.com

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global AR PROTAC Degraders Market, Segmentation by Type:

Oral

Topical

Others

Global AR PROTAC Degraders Market, Segmentation by E3 Ligase:

CRBN

VHL

Others

Global AR PROTAC Degraders Market, Segmentation by AR Target Binding Site:

Ligand Binding Domain (LBD)

DNA Binding Domain (DBD)

+357 96 030922
info@marketpublishers.com

Others

Global AR PROTAC Degraders Market, Segmentation by Application:

Prostate Cancers

Others

Companies Profiled:

BMS

Arvinas

Novartis

Genentech

Hinova Pharmaceuticals

Jiangsu Hengrui Medicine

Kintor Pharmaceutical

Qilu Pharmaceutical

Key Questions Answered:
1. How big is the global AR PROTAC Degraders market?
2. What is the demand of the global AR PROTAC Degraders market?
3. What is the year over year growth of the global AR PROTAC Degraders market?
4. What is the production and production value of the global AR PROTAC Degraders market?
5. Who are the key producers in the global AR PROTAC Degraders market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global AR PROTAC Degraders Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GF8CA2D373A8EN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GF8CA2D373A8EN.html